CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.10+0.17 (+0.44%)
Close on Nov 20, 2026Market cap $3.78BP/E –Yield –
CRISPR Therapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
CRISPR Therapeutics's shares outstanding was 97M at Jun 30, 2026. For fiscal 2025 it was 90M, up 6.6% from the year before. Over ten years it grew 33.4% a year on average. The highest annual figure on record is 90M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 90M | +6.6% |
| FY2024 | Dec 31, 2024 | 84M | +6.5% |
| FY2023 | Dec 31, 2023 | 79M | +1.9% |
| FY2022 | Dec 31, 2022 | 78M | -3.3% |
| FY2021 | Dec 31, 2021 | 80M | +21.9% |
| FY2020 | Dec 31, 2020 | 66M | +15.8% |
| FY2019 | Dec 31, 2019 | 57M | +18.7% |
| FY2018 | Dec 31, 2018 | 48M | +19.7% |
| FY2017 | Dec 31, 2017 | 40M | +226.8% |
| FY2016 | Dec 31, 2016 | 12M | +143.3% |
| FY2015 | Dec 31, 2015 | 5M | +41.5% |
| FY2014 | Dec 31, 2014 | 4M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 97M | +10.8% |
| Q1 FY2026 | Mar 31, 2026 | 96M | +11.8% |
| Q4 FY2025 | Dec 31, 2025 | 95M | +11.5% |
| Q3 FY2025 | Sep 30, 2025 | 91M | +7.1% |
| Q2 FY2025 | Jun 30, 2025 | 87M | +2.5% |
| Q1 FY2025 | Mar 31, 2025 | 86M | +5.1% |
| Q4 FY2024 | Dec 31, 2024 | 85M | +7.3% |
| Q3 FY2024 | Sep 30, 2024 | 85M | +7.3% |
| Q2 FY2024 | Jun 30, 2024 | 85M | +7.4% |
| Q1 FY2024 | Mar 31, 2024 | 82M | +4.0% |
| Q4 FY2023 | Dec 31, 2023 | 80M | +1.7% |
| Q3 FY2023 | Sep 30, 2023 | 79M | +1.8% |
| Q2 FY2023 | Jun 30, 2023 | 79M | +2.0% |
| Q1 FY2023 | Mar 31, 2023 | 79M | +2.0% |
| Q4 FY2022 | Dec 31, 2022 | 78M | -2.0% |
| Q3 FY2022 | Sep 30, 2022 | 78M | +2.3% |
| Q2 FY2022 | Jun 30, 2022 | 78M | -3.7% |
| Q1 FY2022 | Mar 31, 2022 | 77M | +2.8% |
| Q4 FY2021 | Dec 31, 2021 | 80M | +12.1% |
| Q3 FY2021 | Sep 30, 2021 | 76M | +8.8% |
| Q2 FY2021 | Jun 30, 2021 | 80M | +31.0% |
| Q1 FY2021 | Mar 31, 2021 | 75M | +23.3% |
| Q4 FY2020 | Dec 31, 2020 | 71M | +18.3% |
| Q3 FY2020 | Sep 30, 2020 | 70M | +21.8% |
| Q2 FY2020 | Jun 30, 2020 | 61M | +15.5% |
| Q1 FY2020 | Mar 31, 2020 | 61M | +16.8% |
| Q4 FY2019 | Dec 31, 2019 | 60M | +16.5% |
| Q3 FY2019 | Sep 30, 2019 | 58M | +21.5% |
| Q2 FY2019 | Jun 30, 2019 | 53M | +13.5% |
| Q1 FY2019 | Mar 31, 2019 | 52M | +13.5% |
| Q4 FY2018 | Dec 31, 2018 | 52M | +24.1% |
| Q3 FY2018 | Sep 30, 2018 | 47M | +18.2% |
| Q2 FY2018 | Jun 30, 2018 | 47M | +17.4% |
| Q1 FY2018 | Mar 31, 2018 | 46M | +15.5% |
| Q4 FY2017 | Dec 31, 2017 | 42M | +19.0% |
| Q3 FY2017 | Sep 30, 2017 | 40M | +657.5% |
| Q2 FY2017 | Jun 30, 2017 | 40M | – |
| Q1 FY2017 | Mar 31, 2017 | 40M | – |
| Q4 FY2016 | Dec 31, 2016 | 35M | – |
| Q3 FY2016 | Sep 30, 2016 | 5M | – |
See a number that looks wrong?